Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline

ELUTIA INC.

Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.
Proceeds to eliminate outstanding debt, resolve Orthobiologics litigation, and fund NXT-41 advancement without dilution.
Transaction expected to close in Q4 2025, subject to customary closing conditions.
Elutia to focus resources on SimpliDerm franchise and drug-eluting pipeline in the $1.5B US breast reconstruction market.
BofA Securities served as financial advisor to Elutia on the sale.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.